106%+ returns, 97% win rate: A fresh list of AI-picked stock is out NOW
John McCartney, a director at Huron Consulting Group Inc. (NASDAQ:HURN), recently sold a significant portion of his holdings in the company. According to a recent SEC filing, McCartney sold a total of 3,067 shares of common stock on March 12, 2025. The transactions occurred at prices ranging from $143.66 to $145.45 per share, amounting to a total sale value of $441,684. The sale comes as Huron’s stock has shown remarkable strength, delivering a 50% return over the past year. With a market capitalization of $2.4 billion, the company maintains a "GREAT" financial health rating according to InvestingPro analysis.
Following these transactions, McCartney now holds 52,621 shares of Huron Consulting Group. This sale reflects a portion of McCartney’s direct ownership in the company, as indicated in the filing. While this insider sale might draw attention, InvestingPro data reveals that management has been actively buying back shares, suggesting confidence in the company’s outlook. Subscribers can access 10+ additional exclusive ProTips and comprehensive analysis in the Pro Research Report.
In other recent news, Huron Consulting Group reported impressive fourth-quarter 2024 earnings, surpassing analyst expectations with an earnings per share (EPS) of $1.90, compared to the forecasted $1.52. The company also reported a revenue of $399.31 million, exceeding the anticipated $379.99 million. For the full year 2024, Huron’s revenue reached a record $1.49 billion, marking a 9.1% increase from the previous year, while net income rose significantly to $116.6 million. Looking ahead, Huron has issued guidance for 2025, projecting revenues between $1.58 billion and $1.66 billion, with an expected EPS range of $6.80 to $7.60.
Analysts have responded positively to Huron’s strong performance and outlook. Truist Securities increased their price target for Huron to $180, maintaining a Buy rating, citing potential benefits from regulatory changes in healthcare and education sectors. Benchmark also raised its price target to $165, emphasizing Huron’s favorable position amid expected shifts in clinical reimbursement models and NIH funding adjustments. These developments reflect confidence in Huron’s ability to navigate evolving market conditions and capitalize on emerging opportunities.
Additionally, Huron’s strategic initiatives, such as the acquisition of Axia Consulting, have strengthened its service offerings, particularly in digital and managed services. The company plans to host an Investor Day in March 2025 to discuss its strategy and financial goals further. These recent developments highlight Huron’s robust financial health and strategic positioning in its core markets.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.